ClinicalTrials.gg
CompletedNCT00986401Updated Dec 19, 2011Results posted

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

A Phase 1 interventional study of Trospium Chloride (Sanctura XR®) and Metformin hydrochloride (Glucophage®) in Healthy, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-19.

Sponsored by Allergan (part of AbbVie) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.

02

Conditions studied

  • Healthy

Keywords

  • Adults
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight within +/-30% of ideal body weight for height and frame size
  • Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 1 months prior to the screening visit).
  • Willing to abstain from caffeine-containing food and beverages for 24-hours prior to dosing, alcohol-containing food and beverage for 48 hours prior to dosing, and Seville oranges (eg orange marmalade), grapefruit, or grapefruit juice for 7 days prior to the dosing and abstain from all throughout the study.
  • Willing to abstain from taking medications (with the exception of hormonal ) and nonprescription medication including vitamins, food supplements, and herbal preparations for 7 days prior to Day-1 of the first treatment period and throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Known allergy or sensitivity to the study medication(s) (Trospium, Metformin)or its components
  • Current enrollment in an drug or device study or participation in such a study within 30 days of entry into this study.
  • History of myasthenia gravis or closed-angle glaucoma.
  • Considering or scheduled to undergo any surgical procedure during the study.
  • History of alcohol or substance abuse within 1 year prior to Day-1 of the first treatment period.
  • History of serious mental or physical illness.
  • Donated in excess of 500 mL of blood in the 30 days prior to the screening visit.
  • Required treatment with any medications, either prescription or nonprescription (including vitamins, antacids, acid-reducers, food supplements, and herbal preparations, excluding hormonal ), within 7 days prior to Day-1 of the first treatment period during the study.
  • Had an acute illness within 5 days prior to Day-1 of the treatment period.
  • Had a history of or C, a positive test for hepatitis B surface antigen, antibody, a history of (HIV) infection or demonstration of HIV antibodies.
  • Planned radiologic study requiring intravenous contrast administration of iodinated contrast material during the study period Serum Creatinine greater than 1.4 mg/dL.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Glucophage® then Sanctura XR® (AB)

    Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.

    Drug: Metformin hydrochloride (Glucophage®)

  • Experimental
    Sanctura XR® then Glucophage® (BA)

    Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.

    Drug: Trospium Chloride (Sanctura XR®)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®

    Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.

    Time frame: 34 Days

Secondary outcomes

  1. Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®

    Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.

    Time frame: 34 Days

07

Results

Posted Dec 19, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneGlucophage® Then Sanctura XR® (AB)Sanctura XR® Then Glucophage® (BA)
Started2222
Completed2221
Not completed01
Period 2
Participant flow — Period 2
MilestoneGlucophage® Then Sanctura XR® (AB)Sanctura XR® Then Glucophage® (BA)
Started2221
Completed2221
Not completed00

Outcome measures

PrimaryMaximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®

Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.

Time frame:
34 Days
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®
Nanograms per milliliter (ng/mL)Glucophage®Glucophage® + Sanctura XR®
Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®739 ± 263753 ± 252
SecondaryMaximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®

Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.

Time frame:
34 Days
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®
Nanograms per milliliter (ng/mL)Sanctura XR®Sanctura XR® + Glucophage®
Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®1.87 ± 1.441.17 ± 0.71

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glucophage®—0/43 (0%)10/43 (23.3%)
Sanctura XR®—0/44 (0%)3/44 (6.8%)
Sanctura XR® in Combination With Glucophage®—0/44 (0%)13/44 (29.5%)
Most frequent other events
Most frequent other events
EventGlucophage®Sanctura XR®Sanctura XR® in Combination With Glucophage®
HeadacheNervous system disorders4/433/447/44
Abdominal pain upperGastrointestinal disorders3/430/440/44
DiarrhoeaGastrointestinal disorders3/430/443/44
Nasal congestionRespiratory, thoracic and mediastinal disorders0/430/443/44

Baseline characteristics

Age Continuous
Age Continuous(years)Glucophage® Then Sanctura XR® (AB)Sanctura XR® Then Glucophage® (BA)Total
Median31.0 (18 to 44)30.2 (18 to 44)31.0 (18 to 44)
Sex: Female, Male
Sex: Female, Male(Participants)Glucophage® Then Sanctura XR® (AB)Sanctura XR® Then Glucophage® (BA)Total
Female10919
Male121325
08

Study locations

1 site
  • Tempe, Arizona, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2009
First posted
Sep 30, 2009
Start
Oct 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Dec 19, 2011
Last update
Dec 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00986401
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 30, 2009
Start date
Oct 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Dec 19, 2011
Last update
Dec 19, 2011

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trospium chloride · Metformin

Start the discussion